In vivo and in vitro efficacy of amodiaquine against Plasmodium falciparum in an area of Continued Use of 4-aminoquinolines in East Africa

Journal of Infectious Diseases

Volumn 199, Issue 11, 2009, Pages 1575-1582

  Sasi, Philip ^a,b   Abdulrahaman, Abdi ^a,c   Mwai, Leah ^a   Muriithi, Steven ^a   Straimer, Judith ^e   Schieck, Elise ^a,e   Rippert, Anja ^e   Bashraheil, Mahfudh ^a   Salim, Amina ^a   Peshu, Judith ^a   Awuondo, Ken ^a   Lowe, Brett ^a   Pirmohamed, Munir ^d   Winstanley, Peter ^d   Ward, Steve ^d   Nzila, Alexis ^a   Borrmann, Steffen ^a,e,f  

^a KEMRI WELLCOME TRUST RESEARCH PROGRAMME   (Kenya)

^b MUHIMBILI UNIVERSITY OF HEALTH AND ALLIED SCIENCES   (Tanzania)

^c UNIVERSITY OF GLASGOW   (United Kingdom)

^d UNIVERSITY OF LIVERPOOL   (United Kingdom)

^e UNIVERSITY OF HEIDELBERG   (Germany)

^f UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

4 AMINOQUINOLINE; AMODIAQUINE; ARTEMETHER PLUS BENFLUMETOL; DEETHYLAMODIAQUINE;

AFRICA; ARTICLE; CHILD; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; DRUG SENSITIVITY; DRUG TOLERABILITY; DRUG USE; FEMALE; GASTROINTESTINAL SYMPTOM; GROWTH INHIBITION; HUMAN; IN VITRO STUDY; IN VIVO STUDY; INFANT; INFECTION RESISTANCE; MAJOR CLINICAL STUDY; MALARIA; MALE; MINIMUM INHIBITORY CONCENTRATION; NEUTROPENIA; NEUTROPHIL COUNT; NONHUMAN; PARASITE ISOLATION; PLASMODIUM FALCIPARUM; POLYMERASE CHAIN REACTION; PRESCHOOL CHILD; PRIORITY JOURNAL; RESPIRATORY TRACT DISEASE; SCHOOL CHILD; SKIN DISEASE; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT;

AMODIAQUINE; ANIMALS; ANTIMALARIALS; CHILD, PRESCHOOL; COHORT STUDIES; FEMALE; HUMANS; INFANT; KENYA; MALARIA; MALE; OUTPATIENTS; PLASMODIUM FALCIPARUM;

EID: 67650656234     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/598862     Document Type: Article

References (48)

1. Hatton CS, Peto TE, Bunch C, et al. Frequency of severe neutropenia associated with amodiaquine prophylaxis against malaria. Lancet 1986; 1:411-4.
2. Neftel KA, Woodtly W, Schmid M, Frick PG, Fehr J. Amodiaquine induced agranulocytosis and liver damage. Br Med J (Clin Res Ed) 1986; 292:721-3.
3. Olliaro P, Nevill C, LeBras J, et al. Systematic review of amodiaquine treatment in uncomplicated malaria. Lancet 1996; 348:1196-201.
4. World Health Organization (WHO). WHO Expert Committee on Malaria, twentieth report. Vol 30. Geneva: WHO, 2000.
5. Fadat G, Le Bras J, Hengy C, Louis JP, Gimou MM, Verdier F. Efficacy of amodiaquine against chloroquine-resistant malaria in Cameroon. Lancet 1991; 338:1092.
6. Brasseur P, Guiguemde R, Diallo S, et al. Amodiaquine remains effective for treating uncomplicated malaria in West and Central Africa. Trans R Soc Trop Med Hyg 1999; 93:645-50.
7. World Health Organization (WHO). Antimalarial treatment policies. Vol 2008. Geneva: WHO, 2007.
8. Shretta R, Omumbo J, Rapuoda B, Snow RW. Using evidence to change antimalarial drug policy in Kenya. Trop Med Int Health 2000; 5:755-64.
9. Zurovac D, Njogu J, Akhwale W, Hamer DH, Snow RW. Translation of artemether-lumefantrine treatment policy into paediatric clinical practice: an early experience from Kenya. Trop Med Int Health 2008; 13:99-107.
10. East African Network for Monitoring Antimalarial Treatment. The efficacy of antimalarial monotherapies, sulphadoxine-pyrimethamine and amodiaquine in East Africa: implications for sub-regional policy. Trop Med Int Health 2003; 8:860-7.
11. Borrmann S, Faucher JF, Bagaphou T, et al. Atovaquone and proguanil versus amodiaquine for the treatment of Plasmodium falciparum malaria in African infants and young children. Clin Infect Dis 2003; 37: 1441-7.
12. Mutabingwa TK, Anthony D, Heller A, et al. Amodiaquine alone, amodiaquine+sulfadoxine-pyrimethamine, amodiaquine+artesunate, and artemether-lumefantrine for outpatient treatment of malaria in Tanzanian children: a four-arm randomised effectiveness trial. Lancet 2005; 365:1474-80.
13. Holmgren G, Bjorkman A, Gil JP. Amodiaquine resistance is not related to rare findings of pfmdrl gene amplifications in Kenya. Trop Med Int Health 2006; 11:1808-12.
14. Adjuik M, Agnamey P, Babiker A, et al. Amodiaquine-artesunate versus amodiaquine for uncomplicated Plasmodium falciparum malaria in African children: a randomised, multicentre trial. Lancet 2002; 359:1365-72.
15. Tinto H, Rwagacondo C, Karema C, et al. In-vitro susceptibility of Plasmodium falciparum to monodesethylamodiaquine, dihydroartemisinin and quinine in an area of high chloroquine resistance in Rwanda. Trans R Soc Trop Med Hyg 2006; 100:509-14.
16. O'Neill PM, Mukhtar A, Stocks PA, et al. Isoquine and related amodiaquine analogues: a new generation of improved 4-aminoquinoline antimalarials. J Med Chem 2003; 46:4933-45.
17. Mbogo CM, Mwangangi JM, Nzovu J, et al. Spatial and temporal heterogeneity of Anopheles mosquitoes and Plasmodium falciparum transmission along the Kenyan coast. Am J Trop Med Hyg 2003; 68:734-42.
18. O'Meara WP, Bejon P, Mwangi TW, et al. Effect of a fall in malaria transmission on morbidity and mortality in Kilifi, Kenya. Lancet 2008; 372:1555-62.
19. World Health Organization (WHO). Guidelines for the treatment of malaria. Geneva: WHO, 2006.
20. Marsh K, Forster D, Waruiru C, et al. Indicators of life-threatening malaria in African children. N Engl J Med 1995; 332:1399-404.
21. World Health Organization (WHO). Assessment and monitoring of antimalarial drug efficacy for the treatment of uncomplicated falciparum malaria. Geneva: WHO, 2003.
22. Felger I, Tavul L, Beck HP. Plasmodium falciparum: a rapid technique for genotyping the merozoite surface protein 2. Exp Parasitol 1993; 77:372-5.
23. Desjardins RE, Canfield CJ, Haynes JD, Chulay JD. Quantitative assessment of antimalarial activity in vitro by a semiautomated microdilution technique. Antimicrob Agents Chemother 1979; 16:710-8.
24. Udeinya IJ, Graves PM, Carter R, Aikawa M, Miller LH. Plasmodium falciparum: effect of time in continuous culture on binding to human endothelial cells and amelanotic melanoma cells. Exp Parasitol 1983; 56: 207-14.
25. Basco LK, Le Bras J. In vitro activity of monodesethylamodiaquine and amopyroquine against African isolates and clones of Plasmodium falciparum. Am J Trop Med Hyg 1993; 48:120-5.
26. National Institute of Allergy and Infectious Diseases (NIAID). Pediatric toxicity tables. Bethesda, MD: NIAID, 2003.
27. Churchill FC, Mount DL, Patchen LC, Bjorkman A. Isolation, characterization and standardization of a major metabolite of amodiaquine by chromatographic and spectroscopic methods. J Chromatogr 1986; 377: 307-18.
28. Pussard E, Verdier F, Faurisson F, Scherrmann JM, Le Bras J, Blayo MC. Disposition of monodesethylamodiaquine after a single oral dose of amodiaquine and three regimens for prophylaxis against Plasmodium falciparum malaria. Eur J Clin Pharmacol 1987; 33:409-14.
29. Hietala SF, Bhattarai A, Msellem M, et al. Population pharmacokinetics of amodiaquine and desethylamodiaquine in pediatric patients with uncomplicated falciparum malaria. J Pharmacokinet Pharmacodyn 2007; 34:669-86.
30. Childs GE, Boudreau EF, Milhous WK, et al. A comparison of the in vitro activities of amodiaquine and desethylamodiaquine against isolates of Plasmodium falciparum. Am J Trop Med Hyg 1989; 40:7-11.
31. Churchill FC, Patchen LC, Campbell CC, Schwartz IK, Nguyen-Dinh P, Dickinson CM. Amodiaquine as a prodrug: importance of metabolite(s) in the antimalarial effect of amodiaquine in humans. Life Sci 1985; 36: 53-62.
32. Winstanley P, Edwards G, Orme M, Breckenridge A. The disposition of amodiaquine in man after oral administration. Br J Clin Pharmacol 1987; 23:1-7.
33. Krishna S, White NJ. Pharmacokinetics of quinine, chloroquine and amodiaquine: clinical implications. Clin Pharmacokinet 1996; 30:263-99.
34. Pradines B, Tall A, Rogier C, et al. In vitro activities of ferrochloroquine against 55 Senegalese isolates of Plasmodium falciparum in comparison with those of standard antimalarial drugs. Trop Med Int Health 2002; 7:265-70.
35. Pradines B, Mabika Mamfoumbi M, Parzy D, et al. In vitro susceptibility of Gabonese wild isolates of Plasmodium falciparum to artemether, and comparison with chloroquine, quinine, halofantrine and amodiaquine. Parasitology 1998; 117:541-5.
36. Menard D, Yapou F, Manirakiza A, Djalle D, Matsika-Claquin MD, Talarmin A. Polymorphisms in pfcrt, pfmdrl, dhfr genes and in vitro responses to antimalarials in Plasmodium falciparum isolates from Bangui, Central African Republic. Am J Trop Med Hyg 2006; 75:381-7.
37. Looareesuwan S, Phillips RE, White NJ, et al. Intravenous amodiaquine and oral amodiaquine/erythromycin in the treatment of chloroquineresistant falciparum malaria. Lancet 1985; 2:805-8.
38. Dorsey G, Staedke S, Clark TD, et al. Combination therapy for uncomplicated falciparum malaria in Ugandan children: a randomized trial. JAMA 2007; 297:2210-9.
39. Basco L. Field application of in vitro assays for the sensitivity of human malaria parasites to antimalarial drugs. Geneva: World Health Organization, 2007.
40. Borrmann S, Matsiegui PB, Missinou MA, Kremsner PG. Effects of Plasmodium falciparum parasite population size and patient age on early and late parasitological outcomes of antimalarial treatment in children. Antimicrob Agents Chemother 2008; 52:1799-805.
41. Bacon DJ, Jambou R, Fandeur T, et al. World Antimalarial Resistance Network (WARN) II: in vitro antimalarial drug susceptibility. Malar J 2007; 6:120.
42. Sulo J, Chimpeni P, Hatcher J, et al. Chlorproguanil-dapsone versus sulfadoxine-pyrimethamine for sequential episodes of uncomplicated falciparum malaria in Kenya and Malawi: a randomised clinical trial. Lancet 2002; 360:1136-43.
43. Basco LK, Ringwald P. Molecular epidemiology of malaria in Cameroon. XXIV. Trends of in vitro antimalarial drug responses in Yaounde, Cameroon. Am J Trop Med Hyg 2007; 76:20-6.
44. Borrmann S, Adegnika AA, Moussavou F, et al. Short-course regimens of artesunate-fosmidomycin in treatment of uncomplicated Plasmodium falciparum malaria. Antimicrob Agents Chemother 2005; 49:3749-54.
45. Falade C, Makanga M, Premji Z, Ortmann CE, Stockmeyer M, de Palacios PI. Efficacy and safety of artemether-lumefantrine (Coartem) tablets (six-dose regimen) in African infants and children with acute, uncomplicated falciparum malaria. Trans R Soc Trop Med Hyg 2005; 99: 459-67.
46. Bell DJ, Nyirongo SK, Mukaka M, et al. Sulfadoxine-pyrimethaminebased combinations for malaria: a randomised blinded trial to compare efficacy, safety and selection of resistance in Malawi. PLoS ONE 2008; 3:e1578.
47. Naisbitt DJ, Williams DP, O'Neill PM, et al. Metabolism-dependent neutrophil cytotoxicity of amodiaquine: a comparison with pyronaridine and related antimalarial drugs. Chem Res Toxicol 1998; 11:1586-95.
48. Christie G, Breckenridge AM, Park BK. Drug-protein conjugatesXVIII. Detection of antibodies towards the antimalarial amodiaquine and its quinone imine metabolite in man and the rat. Biochem Pharmacol 1989; 38:1451-8.